Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Phase II Study of Liposomal Doxorubicin (Doxil) and Gemcitabine in the Treatment of Women With Metastatic Breast Cancer

NCT00027989 is registered in ClinicalTrials.gov with Pharmatech Oncology as lead sponsor.

NCT NCT00027989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00027989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Phase II Study of Liposomal Doxorubicin (Doxil) and Gemcitabine in the Treatment of Women With Metastatic Breast Cancer
Lead sponsor
Pharmatech Oncology
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2001
Completion date
Not reported
Enrollment
Not reported
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer